沛嘉医疗-B(09996):神普畅™ SeQuent® Please CIS紫杉醇药物涂层颅内球囊扩张导管的注册申请获国家药监局批准

智通财经
4 hours ago

智通财经APP讯,沛嘉医疗-B(09996)发布公告,神普畅™ SeQuent® Please CIS紫杉醇药物涂层颅内球囊扩张导管(“SeQuent® Please CIS”或“该产品”)的注册申请近期已获中国国家药品监督管理局批准。

SeQuent® Please CIS由贝朗医疗(苏州)有限公司(贝朗医疗)注册,是一款基于贝朗医疗成熟药物涂层球囊技术开发的颅内紫杉醇药物涂层球囊扩张导管。在对目标病变进行机械性扩张时,该产品会将涂层的紫杉醇精准释放至病变血管壁,作为抗增殖药物,以有效抑制内膜增生,并长期降低再狭窄的风险。该产品专为颅内血管纤细、迂曲的解剖特点而设计,旨在为颅内血管疾病提供创新的“无植入物”治疗选择。公司附属公司上海加奇生物科技苏州有限公司已取得SeQuent® Please CIS在中国内地的独家分销权。

SeQuent® Please CIS获国家药监局批准进一步扩充了集团的神经介入产品组合,并巩固了集团在颅内动脉粥样硬化性狭窄治疗领域的产品布局。集团将凭借其在神经介入领域已建立的商业化能力,支持SeQuent® Please CIS在中国内地的市场导入及商业化进程。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10